Filtered By:
Cancer: Non-Small Cell Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1077 results found since Jan 2013.
GSE219028 Investigating TIAM1 in NSCLC (RNA-Seq)
Contributors : Joe Maltas ; Angeliki MalliriSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe T lymphoma invasion and metastasis inducing protein 1 (TIAM1) is a guanine nucleotide exchange factor (GEF) that activates the small GTPase RAC1. We have shown that nuclear TIAM1promotes the migration of NSCLC cells. To investigate the requirement for TIAM1 in regulating gene expression of NSCLC cells, we performed RNA-seq on H441 cells transfected with either siRNA for TIAM1 (siTIAM1) or a control siRNA (siControl) to identify differentially expressed genes.
Source: GEO: Gene Expression Omnibus - September 12, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Upregulation of long non ‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib
In conclusion, the upregulation of LINC00460, the expression of which is implicated in osimertinib resistance, in the primary site and plasma of patients with EGFR mutation-positive lung cancer may be associated with a poor prognosis in those treated with osimertinib.PMID:37559586 | PMC:PMC10407845 | DOI:10.3892/ol.2023.13966
Source: Oncology Letters - August 10, 2023 Category: Cancer & Oncology Authors: Yuta Nakano Kazutoshi Isobe Takahiro Yoshizawa Naohisa Urabe Sakae Homma Kazuma Kishi Source Type: research
A pancancer analysis of the oncogenic role of ZNRF2 in human tumours
J Cell Mol Med. 2023 Aug 8. doi: 10.1111/jcmm.17900. Online ahead of print.ABSTRACTFinding effective treatments for cancer requires a thorough understanding of how it develops and progresses. Recent research has revealed the crucial role that Zinc and ring finger 2 (ZNRF2) play in the progression of non-small cell lung cancer (NSCLC) by controlling cell growth and death. However, a comprehensive analysis of ZNRF2's role in cancer as a whole has yet to be conducted. Our study sought to investigate the impact of ZNRF2 on diverse human tumours, as well as the molecular pathways involved, using databases such as TCGA (The Canc...
Source: J Cell Mol Med - August 8, 2023 Category: Molecular Biology Authors: Fujie Shi Yunfei Wu Kai Wang Jiafan Wang Minghui Liu Xinlei Sun Source Type: research
Cabazitaxel-loaded human serum albumin nanoparticles combined with TGF β-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
ConclusionsThe antitumor effect of CTX-HSA-NPs on paclitaxel-resistant NSCLC was higher than that of CTX-Tween, and the toxicity was lower than that of CTX-Tween. TGF β-1 siRNA LNP can treat paclitaxel-resistant NSCLC by inhibiting the express ofTGF β-1 mRNA. The combined treatment of TGF β-1 siRNA LNP and CTX-HSA-NPs could effectively improve the antitumor efficacy of paclitaxel-resistant NSCLC. A combination therapy of chemotherapy and nucleic acid drugs could be an effective approach for treating paclitaxel-resistant NSCLC.
Source: Cancer Nanotechnology - July 29, 2023 Category: Cancer & Oncology Source Type: research
Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research
The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells
Exp Cell Res. 2023 Jul 11:113722. doi: 10.1016/j.yexcr.2023.113722. Online ahead of print.ABSTRACTOsimertinib is a third-generation epidermal growth factor receptor (EGFR)1 tyrosine kinase inhibitor (TKI) approved for the treatment of EGFR-positive patients exhibiting a T790 M resistance mutation after treatment with an earlier generation of EGFR TKIs. However, resistance to osimertinib inevitably develops despite its efficacy, and the resistance mechanisms are complex and not fully understood. We established cell lines with acquired resistance to osimertinib from gefitinib- or erlotinib-resistant NSCLC cells using a dose-...
Source: Experimental Cell Research - July 13, 2023 Category: Cytology Authors: Tae-Gul Lee Hye-Min Kang Seo Yun Kim Hye-Ryoun Kim Cheol Hyeon Kim Source Type: research
STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression
CONCLUSIONS: The expression of STAMBPL1 mRNA is significantly up-regulated in LUAD, promoting the progression of LUAD by down-regulating the expression of DHRS2 and acting as a potential biomarker of LUAD.PMID:37393834 | DOI:10.1016/j.tranon.2023.101728
Source: Translational Oncology - July 2, 2023 Category: Cancer & Oncology Authors: Xiang Yang Liqun Ling Changhong Li Tianqi Hu Chenkang Zhou Jian Chen Yumin Wang Lijuan Hu Source Type: research
